What Does Innovent Biologics Do?

Total employees828
HeadquartersSuzhou
Founded2011

Innovent Biologics, Inc. is a premier biopharmaceutical company established in 2011, dedicated to developing, manufacturing, and commercializing high-quality, innovative medicines for the treatment of oncology, autoimmune disorders, metabolic diseases, ophthalmic conditions, and other significant therapeutic areas. With a mission to make groundbreaking biopharmaceutical drugs affordable and accessible to patients worldwide, Innovent has built a fully-integrated platform encompassing R&D, manufacturing, and commercialization. The company has a robust pipeline of biologic drugs and has successfully launched multiple products, establishing a strong presence in China's biopharmaceutical market with expanding global reach.

Where Is Innovent Biologics's Headquarters?

HQ Function

Serves as the central hub for global R&D, large-scale biopharmaceutical manufacturing, and corporate operations.

Notable Features:

State-of-the-art research laboratories and extensive cGMP-compliant manufacturing facilities capable of producing a diverse portfolio of biologic drugs. The campus is strategically located in Suzhou BioBAY, one of China's leading biotechnology innovation parks.

Work Culture:

A dynamic and innovative work environment driven by scientific excellence, collaboration, and a strong commitment to patient well-being. The culture fosters continuous learning and development in the pursuit of breakthrough therapies.

HQ Significance:

The Suzhou headquarters is critical to Innovent's 'end-to-end' capabilities, from discovery and development through to commercial-scale production, underpinning its rapid growth and contribution to China's biopharmaceutical industry.

Values Reflected in HQ: The headquarters embodies Innovent's core values of innovation, quality, integrity, and patient-centricity, reflected in its advanced infrastructure and commitment to global standards.

Location:

Innovent Biologics supports a range of functions globally, primarily focused on research and development, clinical trials across multiple countries (including China, USA, Australia and others), and strategic partnerships for co-development and commercialization. While its manufacturing and core commercial operations are currently centered in China, the company is actively expanding its global footprint through international clinical studies and collaborations with global pharmaceutical companies to bring its innovative therapies to patients worldwide.

Street Address:

168 Dongping Street, Suzhou Industrial Park

City:

Suzhou

State/Province:

Jiangsu Province

Country:

China

Where Else Does Innovent Biologics Operate Around the World?

Rockville, Maryland, USA

Address: 9700 Great Seneca Highway, Suite 123, Rockville, MD 20850, USA

Supports North American clinical operations and engagement with regulatory bodies like the FDA.

Beijing, China

Address: Specific address not publicly listed, but a significant operational presence.

Manages critical aspects of drug development and commercialization for the important Northern China market and national-level regulatory interactions.

Shanghai, China

Address: Specific address not publicly listed, but a significant operational presence.

Drives commercial strategy and execution in Eastern China, a major economic and healthcare hub, and fosters strategic partnerships.

Hong Kong SAR, China

Address: Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong

Serves as a key interface with the international financial community and supports corporate governance.

Buying Intent Signals for Innovent Biologics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Innovent Biologics? Meet the Executive Team

As of April 2025, Innovent Biologics' leadership includes:

Dr. Michael Dechao Yu (俞德超) - Founder, Chairman and Chief Executive Officer
Dr. Yongjun Liu (刘勇军) - President
Mr. Ronald Ede - Executive Director and Chief Financial Officer
Dr. Hui Zhou (周辉) - Senior Vice President, Head of Global Research and Development
Dr. Samuel Agresta - Chief Medical Officer

Who's Investing in Innovent Biologics?

Innovent Biologics has been backed by several prominent investors over the years, including:

Dr. Michael Dechao Yu (Founder)
Lilly Nederland Holding B.V. (Eli Lilly)
Temasek Holdings (Private) Limited
Capital Group Companies, Inc.
BlackRock, Inc.

What Leadership Changes Has Innovent Biologics Seen Recently?

Hire0
Exits0

Innovent Biologics has maintained a stable core executive leadership team over the past 12 months, with no major publicly announced hires or departures among its top-tier executives (CEO, President, CFO, Head of R&D). The company's leadership continuity supports its ongoing strategic initiatives and growth.

What Technology (Tech Stack) Is Used byInnovent Biologics?

Discover the tools Innovent Biologics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Innovent Biologics Email Formats and Examples

Innovent Biologics likely utilizes common corporate email formats. Based on typical conventions for companies of its size and structure, a probable format would involve a combination of the employee's first and last name with the company domain.

[firstinitial][lastname]@innoventbio.com or [first].[last]@innoventbio.com

Format

jdoe@innoventbio.com or jane.doe@innoventbio.com

Example

75%

Success rate

What's the Latest News About Innovent Biologics?

Innovent Biologics Press ReleaseApril 29, 2024

Innovent Biologics Announces IASLC 2024 Presidential Symposium Presentation of Updated Results from HARMONi-A, a Phase 3 Study of IBI344 (PD-1/LAG-3) in First-Line Squamous NSCLC

Innovent presented updated positive results from the Phase 3 HARMONi-A study of its PD-1/LAG-3 bispecific antibody, IBI344 (sintilimab-LAG-3), in combination with chemotherapy for first-line treatment of squamous non-small cell lung cancer (NSCLC). The findings were featured in a Presidential Symposium at the IASLC 2024 World Conference on Lung Cancer....more

Innovent Biologics Press ReleaseMarch 26, 2024

Innovent Biologics Announces 2023 Annual Results and Business Updates

Innovent reported its financial results for the full year 2023, highlighting significant revenue growth driven by its product portfolio, advancements in its R&D pipeline with multiple clinical milestones, and continued expansion of its commercial capabilities. The company emphasized its strategic focus on innovation and global development....more

Innovent Biologics Press ReleaseMay 15, 2024

Innovent Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of Anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) in China for Advanced Solid Tumors

Innovent announced the first patient has been dosed in a Phase 1 clinical trial in China for IBI389, a Claudin18.2/CD3 bispecific T-cell engaging antibody, for the treatment of patients with advanced solid tumors. This marks another step in expanding their oncology pipeline....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Innovent Biologics, are just a search away.